PharmaEngine, Inc. (TPEX: 4162)
Health Care · Biotechnology · TW
NT$57.20
+3.25% today · -17.5% 1Y
PharmaEngine, Inc. (TPEX: 4162) operates in the Biotechnology industry within the Health Care sector. The company is valued at $257.02M and employs 45 people.
Over the last twelve months the share price has lost 17.5%, trading between 53.00 and 74.40.
Tweenvest scores PharmaEngine, Inc. across four factors: quality 76/100, value 74/100, growth 20/100, dividend 29/100. Its strongest factor is quality.
4162 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $257.02M
- Revenue (TTM)
- $32.22M
- P/E
- 15.26
- EPS
- 3.75
- Dividend yield
- 3.50%
- Beta (5Y)
- 0.11
- 52-week high
- NT$74.40
- 52-week low
- NT$53.00
- Avg volume (3M)
- —
- Shares outstanding
- 143.68M
- Employees
- 45
- Next earnings
- —
About PharmaEngine, Inc.
PharmaEngine, Inc. is a biopharmaceutical firm specializing in the creation and advancement of oncology therapeutics, primarily targeting markets in Taiwan and Europe. Its leading drug candidate is ONIVYDE, an innovative liposomal formulation of irinotecan. This topoisomerase 1 inhibitor is designed to treat metastatic pancreatic cancer. The company's pipeline also includes PEP06, currently in Phase I clinical trials for various cancers, and PEP07. PEP07, a Chk1 inhibitor in preclinical development, is being investigated for its ability to induce DNA damage and programmed cell death (apoptosis), leading to "replication catastrophe" in cancer cells. Established in 2002, PharmaEngine, Inc. maintains its corporate headquarters in Taipei, Taiwan.
- ISIN
- TW0004162003
- Founded
- 2002
- Listed since
- Jun 20, 2012
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Fate Therapeutics, Inc.NasdaqGM: FATE | $261.21M | $2.11 | -3.21% |
| VISEN PharmaceuticalsSEHK: 2561 | $259.19M | HK$18.61 | +0.59% |
| Healios K.K.TSE: 4593 | $258.52M | ¥302.00 | +5.23% |
| Upstream Bio, Inc.NasdaqGS: UPB | $257.42M | $4.70 | -6.75% |
| Immuneering CorporationNasdaqGM: IMRX | $254.91M | $3.94 | -3.19% |
| Amarin Corporation plcNasdaqCM: AMRN | $254.11M | $12.03 | -2.59% |
| Intelligene Inc.TPEX: 7832 | $253.95M | NT$14.00 | +2.56% |
| Vicore Pharma Holding AB (publ)OM: VICO | $253.39M | Skr9.00 | -3.43% |
Figures last refreshed Oct 11, 2026.